We are live on ! Find out more
FATE icon

Fate Therapeutics
FATE

60 hedge funds and large institutions have $86.2M invested in Fate Therapeutics in 2017 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 16 increasing their positions, 13 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 14

23% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 13

13% more funds holding

Funds holding: 53 → 60 (+7)

3.81% more ownership

Funds ownership: 60.47% → 64.28% (+3.8%)

24% less capital invested

Capital invested by funds: $114M → $86.2M (-$27.7M)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
60
Holders Change
+7
Holders Change %
+13.21%
% of All Funds
1.5%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
21
Increased
16
Reduced
13
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$6.02M
2
CC
Casdin Capital
New York
+$2.11M
3
State Street
State Street
Massachusetts
+$1.7M
4
Northern Trust
Northern Trust
Illinois
+$1.28M
5
6CM
683 Capital Management
New York
+$453K

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$5.95M
2
KCM
Kingdon Capital Management
New York
-$2.15M
3
Millennium Management
Millennium Management
New York
-$545K
4
SCM
Segantii Capital Management
Hong Kong
-$182K
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$173K
Name Holding Trade Value Shares
Change 		Change in
Stake
IA
51
IFP Advisors
Florida
$17K -$1.15K -300 -6%
BNP Paribas Financial Markets
52
BNP Paribas Financial Markets
France
$12.9K +$15.3K +3,997 New
AIP
53
Ameritas Investment Partners
Nebraska
$11K +$12.8K +3,346 New
AG
54
Advisor Group
Arizona
$8K +$2.3K +600 +30%
First Manhattan
55
First Manhattan
New York
$4K – – –
VCM
56
Vigilant Capital Management
Maine
$3K – – –
TWA
57
TCI Wealth Advisors
Arizona
$3K +$1.15K +300 +60%
Manulife (Manufacturers Life Insurance)
58
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1K +$142 +37 +20%
SCM
59
Segantii Capital Management
Hong Kong
– -$182K -39,999 Closed
HIM
60
Hillsdale Investment Management
Ontario, Canada
– -$160K -35,200 Closed
DCM
61
Driehaus Capital Management
Illinois
– -$145K -31,790 Closed
VKH
62
Virtu KCG Holdings
New York
– -$111K -24,480 Closed
DTL
63
Dynamic Technology Lab
Singapore
– -$99K -21,654 Closed
GP
64
GLG Partners
United Kingdom
– -$94K -20,754 Closed
BCM
65
BlueCrest Capital Management
Jersey
– -$81K -17,728 Closed
TAM
66
Tocqueville Asset Management
New York
– -$68K -15,000 Closed
Cerity Partners
67
Cerity Partners
New York
– -$63K -13,920 Closed
Citadel Advisors
68
Citadel Advisors
Florida
– -$63K -13,746 Closed
CS
69
Credit Suisse
Switzerland
– -$56K -12,372 Closed
AIM
70
Acrospire Investment Management
Illinois
– -$33.7K -8,800 -100%
Federated Hermes
71
Federated Hermes
Pennsylvania
– -$5K -1,170 Closed
DADC
72
D.A. Davidson & Co
Montana
– -$3K -720 Closed
Citigroup
73
Citigroup
New York
– -$11 -3 -3%
1 2
3

FATE Hedge Fund Activity: Q2 2017 in Review

60 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q2 2017, worth a combined $86.2M — down 24% from $114M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new FATE positions and 14 closed out — a net gain of 7 holders — while 16 added to existing stakes and 13 trimmed.

The largest buyer was BlackRock, adding an estimated $6.02M. The largest seller was BVF Inc, cutting an estimated $5.95M.

  • 60 institutional investors held Fate Therapeutics (FATE) as of Q2 2017, up from 53 in Q1 2017.
  • Funds reported $86.2M of Fate Therapeutics stock for Q2 2017, down 24% quarter-over-quarter.
  • 21 funds opened new Fate Therapeutics positions in Q2 2017 and 14 closed out, a net change of +7 holders.
  • The largest Fate Therapeutics buyer in Q2 2017 was BlackRock, an estimated $6.02M added.
  • The largest Fate Therapeutics seller in Q2 2017 was BVF Inc, an estimated $5.95M sold.

Based on aggregated 13F filings for Q2 2017.